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Like most other industrialized
nations, Switzerland has also
experienced its own version of the
big stem cell debate, but it has led
it to a unique and typically Swiss
solution by referendum. The
debate started in 2000, when
biologist Marisa Jaconi in Geneva
secured funding from the Swiss
National Science Foundation to
start a project using imported
human embryonic stem (ES) cells
for studies of cardiac
differentiation. As the existing laws
did not cover this situation,
politicians were forced to react. By
December 2003, the government
had passed a federal law designed
to legalize stem cell research
along similar lines as it is done in
the United Kingdom. Several
religious and green groups,
however, collected 87,100
signatures to challenge the law,
forcing the government to hold a
referendum on it.
During the year-long debate, the
government toned down parts of
the law (known as the
Stammzellenforschungsgesetz, or
stem cell research law), such that
it will be illegal to create chimeras,
clones, or embryos destined
exclusively for research, thus
ruling out ‘therapeutic cloning’
experiments of the kind that have
recently been approved by the
HFEA in Britain (see Curr. Biol. 14,
R592). Only ‘supernumerary’
embryos (i.e., those that are not
eligible for implantation and would
otherwise be destroyed) may be
used to derive ES cells, and only if
they have developed for less than
seven days.
Late last year, the Swiss
electorate was called to decide on
this revised legal proposition and
thus on the fate of stem cell
research in their country (along
with referenda on a few other,
unrelated issues). The result was
surprisingly clear: precisely two
thirds of the voters approved the
new law, which will thus come into
force in March.
Switzerland already boasts
pharmaceutical giants like Roche
and Novartis, as well as one of the
world-leading universities, the ETH
Zurich. Is the new legal situation
going to turn this small but
extremely wealthy country into a
stem cell paradise as well?
At the moment, there is only a
small number of research groups
interested in stem cell research
(including adult stem cells), which
recently set up the Swiss Stem
Cell Network (SSCN). The network,
chaired by Ariel Ruiz i Altaba of
the University of Geneva, held its
first national meeting in October
2004. Most of the membership of
the network comes from Geneva,
where both the medical and the
science departments have
laboratories interested in stem cell
research. Smaller numbers of
researchers are based at Zurich,
Lausanne and Basel.
None of these groups is likely to
rush into creating human ES cell
lines, as the know-how would
have to be learned abroad and a
variety of cell lines are readily
available. Marisa Jaconi is going
to continue importing stem cells
from WiCell in Wisconsin, US or
from other countries. While this
research was not explicitly
forbidden before the new law, she
welcomes the clarification of the
legal situation. “If the law had
been rejected,” she says, “it would
have been a very difficult situation
to work in a country where the
population is against this type of
research, and it would have been
more difficult to obtain funding.”
She also points out that the
imported stem cells fall under the
same restrictions as any Swiss-
made cell lines would. Thus,
import of stem cells from cloned
embryos or embryos generated
specifically for research is
forbidden. These restrictions
apart, Swiss researchers are free
to import the newest and best
stem cell lines, unlike their
colleagues in neighboring
Germany, who have to make do
with cell lines created before
January 2002.
So far, Jaconi’s group has been
the only one in Switzerland to
import and use ES cells. A handful
of others, including groups at
Lausanne and Zurich are likely to
follow this year. Under the new law
they will have to obtain a project-
specific permission from the
national health office (Bundesamt
für Gesundheit, BAG). Lukas
Sommer, a neurologist at the ETH
Zurich and board member of the
SSCN, who uses fetal and adult
stem cells already, has no
immediate plans to use or create
ES cells, but he says “we
appreciate that we now have the
option to do so”.
The mighty Swiss
pharmaceutical industry has so far
steered clear of the stem cell
debate. Rumor has it that Novartis
may be conducting ES cell
experiments in their US
laboratories, which could under
the new law be transferred back to
the company’s home ground.
By and large, there seems to be
a desire to stay on the safe side of
the hot issue. Thus, the front page
of the SSCN web site
(www.unige.ch/sciences/biologie/
biani/sscn/) carries a prominent
disclaimer distancing the network
from human cloning. Even though
the shores of Lake Geneva were
the location where Mary Shelley
conceived “Frankenstein”, they
are not likely to see any monstrous
misuse of science any time soon.
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